Alzheimer's Research & Therapy最新文献

筛选
英文 中文
Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: a longitudinal observational study 受教育程度、吸烟状况和饮酒障碍与老年人痴呆症风险的关系:一项纵向观察研究
IF 9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-18 DOI: 10.1186/s13195-024-01569-7
Huilin Tang, C. Elizabeth Shaaban, Steven T. DeKosky, Glenn E Smith, Xia Hu, Michael Jaffee, Ramzi G. Salloum, Jiang Bian, Jingchuan Guo
{"title":"Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: a longitudinal observational study","authors":"Huilin Tang, C. Elizabeth Shaaban, Steven T. DeKosky, Glenn E Smith, Xia Hu, Michael Jaffee, Ramzi G. Salloum, Jiang Bian, Jingchuan Guo","doi":"10.1186/s13195-024-01569-7","DOIUrl":"https://doi.org/10.1186/s13195-024-01569-7","url":null,"abstract":"Previous research on the risk of dementia associated with education attainment, smoking status, and alcohol use disorder (AUD) has yielded inconsistent results, indicating potential heterogeneous treatment effects (HTEs) of these factors on dementia risk. Thus, this study aimed to identify the important variables that may contribute to HTEs of these factors in older adults. Using 2005–2021 data from the National Alzheimer’s Coordinating Center (NACC), we included older adults (≥ 65 years) with normal cognition at the first visit. The exposure of interest included college education or above, current smoking, and AUD and the outcome was all-cause dementia. We applied doubly robust learning to estimate risk differences (RD) and 95% confidence intervals (CI) between exposed and unexposed groups in the overall cohort and subgroups identified through a decision tree model. Of 10,062 participants included, 929 developed all-cause dementia over a median 4.4-year follow-up. College education or above was associated with a lower risk of all-cause dementia in the overall population (RD, -1.5%; 95%CI, -2.8 to -0.3), especially among the subpopulations without hypertension, regardless of the APOE4 status. Current smoking was not related to increased dementia risk overall (2.8%; -1.5 to 7.2) but was significantly associated with increased dementia risk among men with (21.1%, 3.1 to 39.1) and without (8.4%, 0.9 to 15.8) cerebrovascular disease. AUD was not related to increased dementia risk overall (2.0%; -7.7 to 11.7) but was significantly associated with increased dementia risk among men with neuropsychiatric disorders (31.5%; 7.4 to 55.7). Our studies identified important factors contributing to HTEs of education, smoking, and AUD on risk of all-cause dementia, suggesting an individualized approach is needed to address dementia disparities.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"123 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease 早期与晚期失忆型阿尔茨海默病的颞叶内侧萎缩模式
IF 9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-16 DOI: 10.1186/s13195-024-01571-z
Anika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, Olof Strandberg, Erik Stomrud, Niklas Mattsson-Carlgren, Shorena Janelidze, Ruben Smith, Sebastian Palmqvist, Hannah Baumeister, David Berron, Paul A. Yushkevich, Oskar Hansson, Nicola Spotorno, Laura E.M. Wisse
{"title":"Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease","authors":"Anika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, Olof Strandberg, Erik Stomrud, Niklas Mattsson-Carlgren, Shorena Janelidze, Ruben Smith, Sebastian Palmqvist, Hannah Baumeister, David Berron, Paul A. Yushkevich, Oskar Hansson, Nicola Spotorno, Laura E.M. Wisse","doi":"10.1186/s13195-024-01571-z","DOIUrl":"https://doi.org/10.1186/s13195-024-01571-z","url":null,"abstract":"The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfields and drivers of atrophy in amnestic EOAD is lacking. BioFINDER-2 participants with memory impairment, abnormal amyloid-β and tau-PET were included. Forty-one amnestic EOAD individuals ≤65 years and, as comparison, late-onset AD (aLOAD, ≥70 years, n = 154) and amyloid-β-negative cognitively unimpaired controls were included. MTL subregions and biomarkers of (co-)pathologies were measured. AD groups showed smaller MTL subregions compared to controls. Atrophy patterns were similar across AD groups: aLOAD showed thinner entorhinal cortices than aEOAD; aEOAD showed thinner parietal regions than aLOAD. aEOAD showed lower white matter hyperintensities than aLOAD. No differences in MTL tau-PET or transactive response DNA binding protein 43-proxy positivity were found. We found evidence for MTL atrophy in amnestic EOAD and overall similar levels to aLOAD of MTL tau pathology and co-pathologies.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"200 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration 淀粉样蛋白和心脏代谢风险因素对神经退行性疾病血浆神经丝蛋白轻链预后能力的影响
IF 9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-12 DOI: 10.1186/s13195-024-01564-y
Keun You Kim, Eosu Kim, Jun-Young Lee
{"title":"Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration","authors":"Keun You Kim, Eosu Kim, Jun-Young Lee","doi":"10.1186/s13195-024-01564-y","DOIUrl":"https://doi.org/10.1186/s13195-024-01564-y","url":null,"abstract":"Plasma neurofilament light chain (NfL) is a blood biomarker of neurodegeneration, including Alzheimer’s disease. However, its usefulness may be influenced by common conditions in older adults, including amyloid-β (Aβ) deposition and cardiometabolic risk factors like hypertension, diabetes mellitus (DM), impaired kidney function, and obesity. This longitudinal observational study using the Alzheimer’s Disease Neuroimaging Initiative cohort investigated how these conditions influence the prognostic capacity of plasma NfL. Non-demented participants (cognitively unimpaired or mild cognitive impairment) underwent repeated assessments including the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores, hippocampal volumes, and white matter hyperintensity (WMH) volumes at 6- or 12-month intervals. Linear mixed-effect models were employed to examine the interaction between plasma NfL and various variables of interest, such as Aβ (evaluated using Florbetapir positron emission tomography), hypertension, DM, impaired kidney function, or obesity. Over a mean follow-up period of 62.5 months, participants with a mean age of 72.1 years (n = 720, 48.8% female) at baseline were observed. Higher plasma NfL levels at baseline were associated with steeper increases in ADAS-Cog scores and WMH volumes, and steeper decreases in hippocampal volumes over time (all p-values < 0.001). Notably, Aβ at baseline significantly enhanced the association between plasma NfL and longitudinal changes in ADAS-Cog scores (p-value 0.005) and hippocampal volumes (p-value 0.004). Regarding ADAS-Cog score and WMH volume, the impact of Aβ was more prominent in cognitively unimpaired than in mild cognitive impairment. Hypertension significantly heightened the association between plasma NfL and longitudinal changes in ADAS-Cog scores, hippocampal volumes, and WMH volumes (all p-values < 0.001). DM influenced the association between plasma NfL and changes in ADAS-Cog scores (p-value < 0.001) without affecting hippocampal and WMH volumes. Impaired kidney function did not significantly alter the association between plasma NfL and longitudinal changes in any outcome variables. Obesity heightened the association between plasma NfL and changes in hippocampal volumes only (p-value 0.026). This study suggests that the prognostic capacity of plasma NfL may be amplified in individuals with Aβ or hypertension. This finding emphasizes the importance of considering these factors in the NfL-based prognostic model for neurodegeneration in non-demented older adults.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"111 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142213241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRanscranial AlterNating current stimulation FOR patients with mild Alzheimer’s Disease (TRANSFORM-AD): a randomized controlled clinical trial 轻度阿尔茨海默病患者的颅内改变电流刺激(TRANSFORM-AD):随机对照临床试验
IF 9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-12 DOI: 10.1186/s13195-024-01570-0
Yi Tang, Yi Xing, Liwei Sun, Zhibin Wang, Changming Wang, Kun Yang, Wei Zhu, Xinrui Shi, Beijia Xie, Yunsi Yin, Yingxin Mi, Tao Wei, Renjie Tong, Yuchen Qiao, Shaozhen Yan, Penghu Wei, Yanfeng Yang, Yongzhi Shan, Xu Zhang, Jianping Jia, Stefan J. Teipel, Robert Howard, Jie Lu, Chunlin Li, Guoguang Zhao
{"title":"TRanscranial AlterNating current stimulation FOR patients with mild Alzheimer’s Disease (TRANSFORM-AD): a randomized controlled clinical trial","authors":"Yi Tang, Yi Xing, Liwei Sun, Zhibin Wang, Changming Wang, Kun Yang, Wei Zhu, Xinrui Shi, Beijia Xie, Yunsi Yin, Yingxin Mi, Tao Wei, Renjie Tong, Yuchen Qiao, Shaozhen Yan, Penghu Wei, Yanfeng Yang, Yongzhi Shan, Xu Zhang, Jianping Jia, Stefan J. Teipel, Robert Howard, Jie Lu, Chunlin Li, Guoguang Zhao","doi":"10.1186/s13195-024-01570-0","DOIUrl":"https://doi.org/10.1186/s13195-024-01570-0","url":null,"abstract":"The mechanistic effects of gamma transcranial alternating current stimulation (tACS) on hippocampal gamma oscillation activity in Alzheimer’s Disease (AD) remains unclear. This study aimed to clarify beneficial effects of gamma tACS on cognitive functioning in AD and to elucidate effects on hippocampal gamma oscillation activity. This is a double-blind, randomized controlled single-center trial. Participants with mild AD were randomized to tACS group or sham group, and underwent 30 one-hour sessions of either 40 Hz tACS or sham stimulation over consecutive 15 days. Cognitive functioning, structural magnetic resonance imaging (MRI), and simultaneous electroencephalography–functional MRI (EEG-fMRI) were evaluated at baseline, the end of the intervention and at 3-month follow-up from the randomization. A total of 46 patients were enrolled (23 in the tACS group, 23 in the sham group). There were no group differences in the change of the primary outcome, 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) score after intervention (group*time, p = 0.449). For secondary outcomes, compared to the control group, the intervention group showed significant improvement in MMSE (group*time, p = 0.041) and MoCA scores (non-parametric test, p = 0.025), which were not sustained at 3-month follow-up. We found an enhancement of theta-gamma coupling in the hippocampus, which was positively correlated with improvements of MMSE score and delayed recall. Additionally, fMRI revealed increase of the local neural activity in the hippocampus. Effects on the enhancement of theta-gamma coupling and neural activity within the hippocampus suggest mechanistic models for potential therapeutic mechanisms of tACS. ClinicalTrials.gov, NCT 03920826; Registration Date: 2019-04-19.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"64 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142213238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, neuropathological, and molecular characteristics of rapidly progressive dementia with Lewy bodies: a distinct clinicopathological entity? 快速进展性路易体痴呆症的临床、神经病理学和分子特征:一个独特的临床病理学实体?
IF 9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-10 DOI: 10.1186/s13195-024-01565-x
Giuseppe Mario Bentivenga, Simone Baiardi, Andrea Mastrangelo, Edoardo Ruggeri, Angela Mammana, Alice Ticca, Marcello Rossi, Sabina Capellari, Piero Parchi
{"title":"Clinical, neuropathological, and molecular characteristics of rapidly progressive dementia with Lewy bodies: a distinct clinicopathological entity?","authors":"Giuseppe Mario Bentivenga, Simone Baiardi, Andrea Mastrangelo, Edoardo Ruggeri, Angela Mammana, Alice Ticca, Marcello Rossi, Sabina Capellari, Piero Parchi","doi":"10.1186/s13195-024-01565-x","DOIUrl":"https://doi.org/10.1186/s13195-024-01565-x","url":null,"abstract":"The term rapidly progressive dementia (RPD) with Lewy bodies (rpDLB) is used for DLB patients who develop a rapidly progressive neurological syndrome and have reduced survival. Here, we characterise the clinical, neuropathological, and molecular characteristics of a large rpDLB neuropathological series. We included all RPD patients with a disease duration < 4 years submitted to our prion disease referral centre between 2003 and 2022 who showed Lewy body pathology (LBP) in limbic or neocortical stages as primary neuropathological diagnosis, had no systemic condition justifying the rapid deterioration and were previously neurologically unimpaired. Clinical features were retrieved and compared with Creutzfeldt-Jakob disease (CJD) and rapidly progressive Alzheimer’s disease (rpAD) cohorts. Neuropathological and genetic (whole exome sequencing, APOE genotyping, and C9orf72 repeat expansion analysis) characteristics of rpDLB patients were systematically investigated. We scored semi-quantitatively the LBP load and performed a α-synuclein (αSyn) RT-QuIC seeding amplification assay (SAA) on cerebrospinal fluid (CSF) and tenfold serially diluted brain homogenates from different brain areas in rpDLB patients and typical long-lasting Lewy body disease (LBD) with dementia patients as control group. RpDLB patients were older (p = 0.047) and presented more cognitive fluctuations (p = 0.005), visual hallucinations (p = 0.020), neuropsychiatric symptoms (p = 0.006) and seizures (p = 0.032), and fewer cerebellar (p < 0.001) and visual (p = 0.004) signs than CJD ones. Delirium onset was more common than in both CJD (p < 0.001) and rpAD (p = 0.008). Atypical LBD signs (pyramidal, myoclonus, akinetic mutism) were common. All tested patients were positive by CSF αSyn SAA. Concomitant pathologies were common, with only four cases showing relatively “pure” LBP. LBP load and αSyn seeding activity measured through αSyn RT-QuIC SAA were not significantly different between rpDLB patients and typical LBD. We found a likely pathogenic variant in GBA in one patient. Our results indicate that: 1) rpDLB exhibits a distinct clinical signature (2) CSF αSyn SAA is a reliable diagnostic test; 3) rpDLB is a heterogeneous neuropathological entity that can be underlain by both widespread pure LBP, or multiple copathologies 4) rpDLB is likely not sustained by distinct αSyn conformational strains; 5) genetic defects may, at least occasionally, contribute to the poor prognosis in these patients.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"7 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer's disease. 通过稳定 F-肌动蛋白缓解阿尔茨海默病的突触和记忆损伤
IF 7.9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-07 DOI: 10.1186/s13195-024-01558-w
Haseena P A, Nimisha Basavaraju, Mahesh Chandran, Abdul Jaleel, David A Bennett, Reddy Peera Kommaddi
{"title":"Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer's disease.","authors":"Haseena P A, Nimisha Basavaraju, Mahesh Chandran, Abdul Jaleel, David A Bennett, Reddy Peera Kommaddi","doi":"10.1186/s13195-024-01558-w","DOIUrl":"10.1186/s13195-024-01558-w","url":null,"abstract":"<p><strong>Background: </strong>Synaptic dysfunction, characterized by synapse loss and structural alterations, emerges as a prominent correlate of cognitive decline in Alzheimer's disease (AD). Actin cytoskeleton, which serves as the structural backbone of synaptic architecture, is observed to be lost from synapses in AD. Actin cytoskeleton loss compromises synaptic integrity, affecting glutamatergic receptor levels, neurotransmission, and synaptic strength. Understanding these molecular changes is crucial for developing interventions targeting synaptic dysfunction, potentially mitigating cognitive decline in AD.</p><p><strong>Methods: </strong>In this study, we investigated the synaptic actin interactome using mass spectrometry in a mouse model of AD, APP/PS1. Our objective was to explore how alterations in synaptic actin dynamics, particularly the interaction between PSD-95 and actin, contribute to synaptic and cognitive impairment in AD. To assess the impact of restoring F-actin levels on synaptic and cognitive functions in APP/PS1 mice, we administered F-actin stabilizing agent, jasplakinolide. Behavioral deficits in the mice were evaluated using the contextual fear conditioning paradigm. We utilized primary neuronal cultures to study the synaptic levels of AMPA and NMDA receptors and the dynamics of PSD-95 actin association. Furthermore, we analyzed postmortem brain tissue samples from subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer's dementia (AD) to determine the association between PSD-95 and actin.</p><p><strong>Results: </strong>We found a significant reduction in PSD-95-actin association in synaptosomes from middle-aged APP/PS1 mice compared to wild-type (WT) mice. Treatment with jasplakinolide, an actin stabilizer, reversed deficits in memory recall, restored PSD-95-actin association, and increased synaptic F-actin levels in APP/PS1 mice. Additionally, actin stabilization led to elevated synaptic levels of AMPA and NMDA receptors, enhanced dendritic spine density, suggesting improved neurotransmission and synaptic strength in primary cortical neurons from APP/PS1 mice. Furthermore, analysis of postmortem human tissue with NCI, MCI and AD subjects revealed disrupted PSD-95-actin interactions, underscoring the clinical relevance of our preclinical studies.</p><p><strong>Conclusion: </strong>Our study elucidates disrupted PSD-95 actin interactions across different models, highlighting potential therapeutic targets for AD. Stabilizing F-actin restores synaptic integrity and ameliorates cognitive deficits in APP/PS1 mice, suggesting that targeting synaptic actin regulation could be a promising therapeutic strategy to mitigate cognitive decline in AD.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"200"},"PeriodicalIF":7.9,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis. 作为阿尔茨海默病和额颞叶变性的生物标志物的脑脊液神经粒蛋白水平:横断面分析。
IF 7.9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-06 DOI: 10.1186/s13195-024-01566-w
Vanesa Jurasova, Ross Andel, Alzbeta Katonova, Katerina Veverova, Terezie Zuntychova, Hana Horakova, Martin Vyhnalek, Tereza Kolarova, Vaclav Matoska, Kaj Blennow, Jakub Hort
{"title":"CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.","authors":"Vanesa Jurasova, Ross Andel, Alzbeta Katonova, Katerina Veverova, Terezie Zuntychova, Hana Horakova, Martin Vyhnalek, Tereza Kolarova, Vaclav Matoska, Kaj Blennow, Jakub Hort","doi":"10.1186/s13195-024-01566-w","DOIUrl":"10.1186/s13195-024-01566-w","url":null,"abstract":"<p><strong>Background: </strong>There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum.</p><p><strong>Methods: </strong>Participants with subjective cognitive decline (SCD) (n = 33), amnestic mild cognitive impairment (aMCI) due to AD (n = 109), AD dementia (n = 67), MCI due to FTLD (n = 25), and FTLD dementia (n = 29) were recruited from the Czech Brain Aging Study. One-way analysis of covariance (ANCOVA) assessed Ng levels in diagnostic subgroups. Linear regressions evaluated the relationship between CSF Ng levels, memory scores, and APOE polymorphism.</p><p><strong>Results: </strong>Ng levels were higher in aMCI-AD patients compared to MCI-FTLD (F[1, 134] = 15.16, p < .001), and in AD-dementia compared to FTLD-dementia (F[1, 96] = 4.60, p = .029). Additionally, Ng levels were higher in FTLD-dementia patients compared to MCI-FTLD (F[1, 54]= 4.35, p = .034), lower in SCD participants compared to aMCI-AD (F[1, 142] = 10.72, p = .001) and AD-dementia (F[1, 100] = 20.90, p < .001), and did not differ between SCD participants and MCI-FTLD (F[1, 58]= 1.02, p = .491) or FTLD-dementia (F[1, 62]= 2.27, p = .051). The main effect of diagnosis across the diagnostic subgroups on Aβ<sub>1-42</sub>/Ng ratio was significant too (F[4, 263]=, p < .001). We found a non-significant association between Ng levels and memory scores overall (β=-0.25, p = .154) or in AD diagnostic subgroups, and non-significant differences in this association between overall AD APOE ε4 carriers and non-carriers (β=-0.32, p = .358).</p><p><strong>Conclusions: </strong>In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The Aβ<sub>1-42</sub>/Ng ratio discriminated AD from FTLD patients better than Ng alone. CSF Ng levels were not related to memory in AD or FTLD, suggesting that Ng may be a marker of the biological signs of disease state rather than cognitive deficits.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"199"},"PeriodicalIF":7.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method. 从病历分析中评估临床痴呆评级量表的可靠性与参考方法的比较。
IF 7.9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-05 DOI: 10.1186/s13195-024-01567-9
Virginie Dauphinot, Sylvain Calvi, Claire Moutet, Jing Xie, Sophie Dautricourt, Anthony Batsavanis, Pierre Krolak-Salmon, Antoine Garnier-Crussard
{"title":"Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.","authors":"Virginie Dauphinot, Sylvain Calvi, Claire Moutet, Jing Xie, Sophie Dautricourt, Anthony Batsavanis, Pierre Krolak-Salmon, Antoine Garnier-Crussard","doi":"10.1186/s13195-024-01567-9","DOIUrl":"10.1186/s13195-024-01567-9","url":null,"abstract":"<p><strong>Background: </strong>The Clinical Dementia Rating (CDR) scale allows to detect the presence of dementia and to assess its severity, however its evaluation requires a significant time (45 min). We evaluated the agreement between two methods of collection of the CDR: face-to-face interview or based on the information available in the patient's medical record.</p><p><strong>Methods: </strong>The CLIMER study was conducted among patients attending a memory center. The CDR scale was evaluated during face-to-face interviews between neuropsychologists and patients and their caregivers and based on blind analysis of the information of the patients' medical record by neuropsychologists. The agreement of the CDR sum of boxes (CDR-SB), the 5-point scale CDR and the different domains of the CDR evaluated between the different methods was measured using intraclass correlation (ICC) coefficient, Bland and Altman method, and linearly weighted Kappa.</p><p><strong>Results: </strong>The study included 139 patients (means ± SD age 80.1 ± 6, 58.3% women, 71.9% with dementia). The ICC for the CDR-SB score assessed by face-to-face and with all the information available in the patient's medical record was 0.95 (95% CI: 0.93-0.97). The mean difference between the CDR-SB score assessed by face-to-face and with the medical record was 0.098 ± 1.036, and 92.4% of the patients lay within the 95% limits of agreement. The ICC for the 5-point scale CDR assessed by face-to-face and with the patient's medical record was 0.92 (95% CI: 0.88-0.95) when all the available information of the patient's medical record was used. The linear weighted Kappa coefficients was 0.79 (95% CI: 0.68-0.91) for the 5-point scale CDR comparison between the two evaluation methods. The analysis by domain of the CDR showed ICC ranging from 0.65 to 0.91 depending of the domains and the methods of evaluation.</p><p><strong>Conclusion: </strong>This study showed an excellent level of agreement of the evaluation of the CDR- SB and the 5-point scale CDR when using all the information of the patient's medical record compared to the face-to-face interview.</p><p><strong>Trial registration: </strong>https//clinicaltrials.gov/ct2/show/NCT04763941 Registration Date 02/17/2021.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"198"},"PeriodicalIF":7.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer's disease. 一种新型 PDHK 抑制剂可恢复阿尔茨海默病模型 5xFAD 小鼠的认知功能障碍并限制其神经退行性变,但不会影响其淀粉样病理学。
IF 7.9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-05 DOI: 10.1186/s13195-024-01552-2
Katsuya Sakimura, Takashi Kawai, Reiko Nashida, Yuji Ishida, Kana Harada, Takashi Suzuki, Chihiro Okuma, Gregory M Cole
{"title":"A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer's disease.","authors":"Katsuya Sakimura, Takashi Kawai, Reiko Nashida, Yuji Ishida, Kana Harada, Takashi Suzuki, Chihiro Okuma, Gregory M Cole","doi":"10.1186/s13195-024-01552-2","DOIUrl":"10.1186/s13195-024-01552-2","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is the most common form of dementia. Although drugs focusing on reducing amyloid β slow progression, they fail to improve cognitive function. Deficits in glucose metabolism are reflected in FDG-PET and parallel the neurodegeneration and synaptic marker loss closely preceding cognitive decline, but the role of metabolic deficits as a cause or consequence of neurodegeneration is unclear. Pyruvate dehydrogenase (PDH) is lost in AD and an important enzyme connecting glycolysis and the tricarboxylic acid (TCA) cycle by converting pyruvate into acetyl-CoA. It is negatively regulated by pyruvate dehydrogenase kinase (PDHK) through phosphorylation.</p><p><strong>Methods: </strong>In the present study, we assessed the in vitro/ in vivo pharmacological profile of the novel PDHK inhibitor that we discovered, Compound A. We also assessed the effects of Compound A on AD-related phenotypes including neuron loss and cognitive impairment using 5xFAD model mice.</p><p><strong>Results: </strong>Compound A inhibited human PDHK1, 2 and 3 but had no inhibitory activity on PDHK4. In primary neurons, Compound A enhanced pyruvate and lactate utilization, but did not change glucose levels. In contrast, in primary astrocytes, Compound A enhanced pyruvate and glucose utilization and enhanced lactate production. In an efficacy study using 5xFAD mice, Compound A ameliorated the cognitive dysfunction in the novel object recognition test and Morris water maze. Moreover, Compound A prevented neuron loss in the hippocampus and cerebral cortex of 5xFAD without affecting amyloid β deposits.</p><p><strong>Conclusions: </strong>These results suggest ameliorating metabolic deficits by activating PDH by Compound A can limit neurodegeneration and is a promising therapeutic strategy for treating AD.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"197"},"PeriodicalIF":7.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study. 脑淀粉样变性血管病的神经精神症状和终生智力活动--一项横断面研究。
IF 7.9 1区 医学
Alzheimer's Research & Therapy Pub Date : 2024-09-04 DOI: 10.1186/s13195-024-01519-3
Marc Dörner, Anthony Tyndall, Nicolin Hainc, Roland von Känel, Katja Neumann, Sebastian Euler, Frank Schreiber, Philipp Arndt, Erelle Fuchs, Cornelia Garz, Wenzel Glanz, Michaela Butryn, Jan Ben Schulze, Sarah Lavinia Florence Schiebler, Anna-Charlotte John, Annkatrin Hildebrand, Andreas B Hofmann, Lena Machetanz, Johannes Kirchebner, Pawel Tacik, Alexander Grimm, Robin Jansen, Marc Pawlitzki, Solveig Henneicke, Jose Bernal, Valentina Perosa, Emrah Düzel, Sven G Meuth, Stefan Vielhaber, Hendrik Mattern, Stefanie Schreiber
{"title":"Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study.","authors":"Marc Dörner, Anthony Tyndall, Nicolin Hainc, Roland von Känel, Katja Neumann, Sebastian Euler, Frank Schreiber, Philipp Arndt, Erelle Fuchs, Cornelia Garz, Wenzel Glanz, Michaela Butryn, Jan Ben Schulze, Sarah Lavinia Florence Schiebler, Anna-Charlotte John, Annkatrin Hildebrand, Andreas B Hofmann, Lena Machetanz, Johannes Kirchebner, Pawel Tacik, Alexander Grimm, Robin Jansen, Marc Pawlitzki, Solveig Henneicke, Jose Bernal, Valentina Perosa, Emrah Düzel, Sven G Meuth, Stefan Vielhaber, Hendrik Mattern, Stefanie Schreiber","doi":"10.1186/s13195-024-01519-3","DOIUrl":"10.1186/s13195-024-01519-3","url":null,"abstract":"<p><strong>Background: </strong>While several studies in cerebral amyloid angiopathy (CAA) focus on cognitive function, data on neuropsychiatric symptoms (NPS) and lifelong mental activities in these patients are scarce. Since NPS are associated with functional impairment, faster cognitive decline and faster progression to death, replication studies in more diverse settings and samples are warranted.</p><p><strong>Methods: </strong>We prospectively recruited n = 69 CAA patients and n = 18 cognitively normal controls (NC). The number and severity of NPS were assessed using the Alzheimer's Disease (AD) Assessment Scale's (ADAS) noncognitive subscale. We applied different regression models exploring associations between NPS number or severity and group status (CAA vs. NC), CAA severity assessed with magnetic resonance imaging (MRI) or cognitive function (Mini-Mental State Examination (MMSE), ADAS cognitive subscale), adjusting for age, sex, years of education, arterial hypertension, AD pathology, and apolipoprotein E status. Mediation analyses were performed to test indirect effects of lifelong mental activities on CAA severity and NPS.</p><p><strong>Results: </strong>Patients with CAA had 4.86 times (95% CI 2.20-10.73) more NPS and 3.56 units (95% CI 1.94-5.19) higher expected NPS severity than NC. Higher total CAA severity on MRI predicted 1.14 times (95% CI 1.01.-1.27) more NPS and 0.57 units (95% CI 0.19-0.95) higher expected NPS severity. More severe white matter hyperintensities were associated with 1.21 times more NPS (95% CI 1.05-1.39) and 0.63 units (95% CI 0.19-1.08) more severe NPS. NPS number (MMSE mean difference - 1.15, 95% CI -1.67 to -0.63; ADAS cognitive mean difference 1.91, 95% CI 1.26-2.56) and severity (MMSE - 0.55, 95% CI -0.80 to -0.30; ADAS cognitive mean difference 0.89, 95% CI 0.57-1.21) predicted lower cognitive function. Greater lifelong mental activities partially mediated the relationship between CAA severity and NPS (indirect effect 0.05, 95% CI 0.0007-0.13), and greater lifelong mental activities led to less pronounced CAA severity and thus to less NPS (indirect effect - 0.08, 95% CI -0.22 to -0.002).</p><p><strong>Discussion: </strong>This study suggests that NPS are common in CAA, and that this relationship may be driven by CAA severity. Furthermore, NPS seem to be tied to lower cognitive function. However, lifelong mental activities might mitigate the impact of NPS in CAA.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"196"},"PeriodicalIF":7.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信